Financhill
Buy
58

SLNO Quote, Financials, Valuation and Earnings

Last price:
$49.13
Seasonality move :
25.88%
Day range:
$48.29 - $52.46
52-week range:
$36.61 - $60.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,331.05x
P/B ratio:
8.01x
Volume:
524.7K
Avg. volume:
431.3K
1-year change:
4.33%
Market cap:
$2.1B
Revenue:
--
EPS (TTM):
-$3.35

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SLNO
Soleno Therapeutics
-- -- -- -- $74.29
ALNY
Alnylam Pharmaceuticals
$580.6M -$0.14 19.93% -17.95% $299.57
KRYS
Krystal Biotech
$91.4M $1.85 116.67% 497.44% $206.25
LEGN
Legend Biotech
$179M -$0.38 108.63% -3.13% $79.50
PTCT
PTC Therapeutics
$249M -$0.65 -37.97% -75.73% $61.71
VRTX
Vertex Pharmaceuticals
$2.9B $4.35 5.88% 2.19% $497.87
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SLNO
Soleno Therapeutics
$49.17 $74.29 $2.1B -- $0.00 0% 2,331.05x
ALNY
Alnylam Pharmaceuticals
$256.45 $299.57 $33.2B -- $0.00 0% 14.56x
KRYS
Krystal Biotech
$153.24 $206.25 $4.4B 86.09x $0.00 0% 18.67x
LEGN
Legend Biotech
$36.42 $79.50 $6.7B -- $0.00 0% 12.77x
PTCT
PTC Therapeutics
$51.82 $61.71 $4B -- $0.00 0% 4.40x
VRTX
Vertex Pharmaceuticals
$459.00 $497.87 $117.9B 26.10x $0.00 0% 10.80x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SLNO
Soleno Therapeutics
-- -0.291 -- --
ALNY
Alnylam Pharmaceuticals
93.86% 1.214 3.37% 2.61x
KRYS
Krystal Biotech
-- 4.082 -- 7.66x
LEGN
Legend Biotech
21% 2.450 3.32% 4.86x
PTCT
PTC Therapeutics
-37.06% -0.204 9.99% 1.99x
VRTX
Vertex Pharmaceuticals
-- 1.257 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SLNO
Soleno Therapeutics
-- -$79.3M -- -- -- -$15.1M
ALNY
Alnylam Pharmaceuticals
$490.3M -$105.2M -29.16% -- -26.13% -$103.8M
KRYS
Krystal Biotech
$77.2M $34.9M 6.45% 6.45% 41.67% $57.8M
LEGN
Legend Biotech
$104.7M -$70.1M -23.33% -28.87% -72.02% -$77.9M
PTCT
PTC Therapeutics
$185.9M -$52M -425.51% -- -28.65% -$87.8M
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

Soleno Therapeutics vs. Competitors

  • Which has Higher Returns SLNO or ALNY?

    Alnylam Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -14.12%. Soleno Therapeutics's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.83 --
    ALNY
    Alnylam Pharmaceuticals
    82.67% -$0.65 $1.1B
  • What do Analysts Say About SLNO or ALNY?

    Soleno Therapeutics has a consensus price target of $74.29, signalling upside risk potential of 51.08%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $299.57 which suggests that it could grow by 16.82%. Given that Soleno Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    4 0 0
    ALNY
    Alnylam Pharmaceuticals
    11 8 1
  • Is SLNO or ALNY More Risky?

    Soleno Therapeutics has a beta of -1.460, which suggesting that the stock is 245.95% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.352, suggesting its less volatile than the S&P 500 by 64.85%.

  • Which is a Better Dividend Stock SLNO or ALNY?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or ALNY?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Soleno Therapeutics's net income of -$76.6M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,331.05x versus 14.56x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,331.05x -- -- -$76.6M
    ALNY
    Alnylam Pharmaceuticals
    14.56x -- $593.2M -$83.8M
  • Which has Higher Returns SLNO or KRYS?

    Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 32.42%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 6.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.83 --
    KRYS
    Krystal Biotech
    92.03% $0.91 $885.8M
  • What do Analysts Say About SLNO or KRYS?

    Soleno Therapeutics has a consensus price target of $74.29, signalling upside risk potential of 51.08%. On the other hand Krystal Biotech has an analysts' consensus of $206.25 which suggests that it could grow by 34.59%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    4 0 0
    KRYS
    Krystal Biotech
    7 1 0
  • Is SLNO or KRYS More Risky?

    Soleno Therapeutics has a beta of -1.460, which suggesting that the stock is 245.95% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.581%.

  • Which is a Better Dividend Stock SLNO or KRYS?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or KRYS?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $83.8M. Soleno Therapeutics's net income of -$76.6M is lower than Krystal Biotech's net income of $27.2M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 86.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,331.05x versus 18.67x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,331.05x -- -- -$76.6M
    KRYS
    Krystal Biotech
    18.67x 86.09x $83.8M $27.2M
  • Which has Higher Returns SLNO or LEGN?

    Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of -78.23%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -28.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.83 --
    LEGN
    Legend Biotech
    65.38% -$0.70 $1.4B
  • What do Analysts Say About SLNO or LEGN?

    Soleno Therapeutics has a consensus price target of $74.29, signalling upside risk potential of 51.08%. On the other hand Legend Biotech has an analysts' consensus of $79.50 which suggests that it could grow by 118.27%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    4 0 0
    LEGN
    Legend Biotech
    11 2 0
  • Is SLNO or LEGN More Risky?

    Soleno Therapeutics has a beta of -1.460, which suggesting that the stock is 245.95% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or LEGN?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or LEGN?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $160.2M. Soleno Therapeutics's net income of -$76.6M is higher than Legend Biotech's net income of -$125.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,331.05x versus 12.77x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,331.05x -- -- -$76.6M
    LEGN
    Legend Biotech
    12.77x -- $160.2M -$125.3M
  • Which has Higher Returns SLNO or PTCT?

    PTC Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -54.2%. Soleno Therapeutics's return on equity of -- beat PTC Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.83 --
    PTCT
    PTC Therapeutics
    94.49% -$1.39 -$769.2M
  • What do Analysts Say About SLNO or PTCT?

    Soleno Therapeutics has a consensus price target of $74.29, signalling upside risk potential of 51.08%. On the other hand PTC Therapeutics has an analysts' consensus of $61.71 which suggests that it could grow by 19.09%. Given that Soleno Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Soleno Therapeutics is more attractive than PTC Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    4 0 0
    PTCT
    PTC Therapeutics
    6 3 1
  • Is SLNO or PTCT More Risky?

    Soleno Therapeutics has a beta of -1.460, which suggesting that the stock is 245.95% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.625, suggesting its less volatile than the S&P 500 by 37.542%.

  • Which is a Better Dividend Stock SLNO or PTCT?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or PTCT?

    Soleno Therapeutics quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Soleno Therapeutics's net income of -$76.6M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,331.05x versus 4.40x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,331.05x -- -- -$76.6M
    PTCT
    PTC Therapeutics
    4.40x -- $196.8M -$106.7M
  • Which has Higher Returns SLNO or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of 31.35%. Soleno Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.83 --
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About SLNO or VRTX?

    Soleno Therapeutics has a consensus price target of $74.29, signalling upside risk potential of 51.08%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.87 which suggests that it could grow by 8.47%. Given that Soleno Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    4 0 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is SLNO or VRTX More Risky?

    Soleno Therapeutics has a beta of -1.460, which suggesting that the stock is 245.95% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.713%.

  • Which is a Better Dividend Stock SLNO or VRTX?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or VRTX?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Soleno Therapeutics's net income of -$76.6M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,331.05x versus 10.80x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,331.05x -- -- -$76.6M
    VRTX
    Vertex Pharmaceuticals
    10.80x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Tesla Stock Falling?
Why Is Tesla Stock Falling?

Tesla stock reached an all-time high of $479.86 on December…

Is DoorDash a Buy, Sell or Hold?
Is DoorDash a Buy, Sell or Hold?

Gig economy food delivery service DoorDash (NASDAQ:DASH) has been running…

Is Clorox’s Dividend Worth It?
Is Clorox’s Dividend Worth It?

Clorox (NYSE:CLX) is the parent company of some of the…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 116x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
87
PCOR alert for Feb 15

Procore Technologies [PCOR] is up 16.3% over the past day.

Buy
54
DKNG alert for Feb 15

DraftKings [DKNG] is up 15.24% over the past day.

Sell
30
TWLO alert for Feb 15

Twilio [TWLO] is down 15.01% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock